3 results
Part A - CX-2009 Monotherapy: Every 21-Day Dosing RegimenThe primary objective of Part A is to determine the safety profile of CX-2009, the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the dose-limiting toxicities(DLTs) of CX-…
Primary Objective: Assess the ability of MRCP+ and LMS to detect change in total biliary volume and cT1 value, 8 weeks after endoscopic treatment of dominant strictures, by a clinical decision rule.Secondary Objective(s): Comparison of baseline MRCP…
This study investigates the correlation between IOS and the severity of fibrosis on HRCT in patients with IPF. It also investigates which IOS parameter best relates to the degree of fibrosis on the HRCT. Furthermore, as a secondary endpoint, it is…